EX-32.1 4 janx-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Janux Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 10, 2022

 

By:

/s/ David Campbell

 

 

 

David Campbell, Ph.D.

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

Date: November 10, 2022

 

By:

/s/ Tighe Reardon

 

 

 

Tighe Reardon

 

 

 

Acting Chief Financial Officer

(Principal Financial and Accounting Officer)